Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that administering adipose-derived stem cells with ATP improved hair regrowth in male mice with androgenetic alopecia, while the combination was less effective in female mice.

This study found that scalp microinfusion with dutasteride using microneedling and tattoo devices appears safe and shows promise as a treatment for male androgenetic alopecia, resulting in stabilization or improvement in 96.7% of patients, although further controlled studies are needed.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This abstract does not contain research results or findings.

The technique effectively promotes hair growth in young men with androgenetic alopecia.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.

This study observed that dutasteride treatment led to improvement in acne vulgaris among two male patients with androgenetic alopecia, suggesting its potential as a treatment option for concurrent conditions.

This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.

This case report highlights significant hair regrowth in a Malaysian woman with localized alopecia areata after intralesional triamcinolone acetonide treatment at a concentration of 5 mg/mL.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study review reports that alopecia areata is often associated with autoimmune thyroid diseases like Hashimoto thyroiditis, suggesting targeted thyroid screening based on symptoms and risk factors may improve detection while minimizing unnecessary tests.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

A man developed alopecia areata after starting cancer treatment with vandetanib.

This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.

This study found that chronic administration of dutasteride in rats did not affect spermatogenesis or oxidative stress in the testes, although it altered hormone levels.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

In this study, 60% of patients with alopecia totalis showed partial hair regrowth after being treated with triamcinolone acetonide injections, with one patient achieving complete regrowth and responding well to further immunotherapy.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

Dutasteride injections can help treat hair loss in men and women.

Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.